FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Novo A/S

2. Date of Event Requiring Statement (MM/DD/YYYY)
5/4/2015 

3. Issuer Name and Ticker or Trading Symbol

Tibira Therapeutics, Inc. [TBRA]

(Last)        (First)        (Middle)

TUBORG HAVNEVEJ 19

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

HELLERUP, G7 2900       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
COMMON STOCK   1858364   (1) (2) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  On January 14, 2015, Regado Biosciences, Inc. ("Regado") and Tobira Therapeutics, Inc. ("Original Tobira") entered into an Agreement and Plan of Merger and Reorganization, as amended on January 23, 2015 (the "Merger Agreement") providing for the merger of a wholly owned subsidiary of Regado with and into Original Tobira, with Original Tobira (hereinafter, the "Surviving Subsidiary") surviving the merger as a wholly owned subsidiary of Regado. On May 4, 2015 (the "Effective Time"), the merger was consummated. At the Effective Time, Regado effected a name change to "Tobira Therapeutics, Inc." (hereinafter, the "Issuer") and the Surviving Subsidiary effected a name change to Tobira Development, Inc.
( 2)  Represents the number of shares of common stock of the Issuer received by the Reporting Person upon consummation of the merger. Each share of Original Tobira common stock held at the Effective Time (after conversion of preferred stock, warrants and outstanding convertible promissory notes plus accrued interest, as adjusted for the 1-for-9 reverse split of common stock effected by the Issuer prior to the consummation of the merger) was exchanged for 1.4302195557 shares of the Issuer's common stock. Certain of the shares are currently held in escrow and are subject to forfeiture during the one year period following the Effective Time to satisfy any indemnification obligations under the Merger Agreement.

Remarks:
Novo A/S is a Danish limited liability company. The board of directors of Novo A/S (the "Novo Board"), currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Novo A/S
TUBORG HAVNEVEJ 19
HELLERUP, G7 2900
X


Signatures
/s/ Bjarne Graven Larsen, Chief Financial Officer of Novo A/S 5/5/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
REGADO BIOSCIENCES INC (NASDAQ:RGDO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more REGADO BIOSCIENCES INC Charts.
REGADO BIOSCIENCES INC (NASDAQ:RGDO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more REGADO BIOSCIENCES INC Charts.